Login
Toggle sidebar

Lint: multiple-myeloma-1

Adjectival Hyphens
error

"Stem-cell harvest and autologous haematopoietic stem cell transplant post-chemotherapeutic/radiotherapy bone marrow ablation are also used, although relapse is inevitable."

Line 192:80 · Only use medical adjectival hyphens where the letters at the end and start of the compound word are the same, e.g. post-transplant. In this case, don't use the hyphen: 'post-chemotherapeutic/radiotherapy'.
Acronyms
warning

"Multiple myeloma accounts for one of the Ms in the popular mnemonic for lucent bone lesions, FEGNOMASHIC."

Line 2:100 · 'FEGNOMASHIC' has no definition. Spell it out if it's unfamiliar to the audience.

"amyloidosis (AL type)"

Line 89:28 · 'AL' has no definition. Spell it out if it's unfamiliar to the audience.

"The initial presentation occasionally is a polyneuropathy when it is part of POEMS syndrome (mostly the sclerotic form)."

Line 92:84 · 'POEMS' has no definition. Spell it out if it's unfamiliar to the audience.
Colons
warning

"Multiple myeloma is a common malignancy in patients above 40; 70% of cases are diagnosed between ages 50 and 70, with a median age of diagnosis being 70 years; there is a male predilection (M: F 2:1) 7,12,14. It accounts for 1% of all malignancies and 10-15% of all haematological neoplasms 12,14. Black populations are affected at nearly twice the rate as White populations 14. Multiple myeloma and osteosarcoma combined account for ~50% of all primary bone malignancies 7."

Line 15:195 · The first word after a colon should almost always be lowercase. In this case, it's not: ': F 2:1'.
Strong
warning

"Presentation may also be with a complication, including:"

Line 64:4 · Generally, don't use bold in text: 'Presentation may also be with a<strong> </strong>complication, including'
List Caps
warning

"Waldenström macroglobulinaemia: IgM paraprotein"

Line 205:15 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Staging"

Line 102:1 · "Staging" is not a recognised heading for this article type.

"Distribution"

Line 104:1 · "Distribution" is not a recognised heading for this article type.

"Signal characteristics"

Line 153:1 · "Signal characteristics" is not a recognised heading for this article type.

"Bone scintigraphy"

Line 186:1 · "Bone scintigraphy" is not a recognised heading for this article type.

"FDG PET-CT"

Line 188:1 · "FDG PET-CT" is not a recognised heading for this article type.

"Response assessment"

Line 193:1 · "Response assessment" is not a recognised heading for this article type.

"Complications"

Line 195:1 · "Complications" is under the wrong parent heading (found under "Treatment and prognosis").
Semicolons
suggestion

"Multiple myeloma is a common malignancy in patients above 40; 70% of cases are diagnosed between ages 50 and 70, with a median age of diagnosis being 70 years; there is a male predilection (M: F 2:1) 7,12,14. It accounts for 1% of all malignancies and 10-15% of all haematological neoplasms 12,14. Black populations are affected at nearly twice the rate as White populations 14. Multiple myeloma and osteosarcoma combined account for ~50% of all primary bone malignancies 7."

Line 15:64 · Use semicolons judiciously.

"Multiple myeloma is a common malignancy in patients above 40; 70% of cases are diagnosed between ages 50 and 70, with a median age of diagnosis being 70 years; there is a male predilection (M: F 2:1) 7,12,14. It accounts for 1% of all malignancies and 10-15% of all haematological neoplasms 12,14. Black populations are affected at nearly twice the rate as White populations 14. Multiple myeloma and osteosarcoma combined account for ~50% of all primary bone malignancies 7."

Line 15:162 · Use semicolons judiciously.
Inline EG
suggestion

"long bone fracture (e.g. proximal femur)"

Line 70:27 · Consider replacing a bracketed e.g. with an inline e.g. after a comma.

"assess possible mechanical complications (e.g. pathological fracture)"

Line 119:49 · Consider replacing a bracketed e.g. with an inline e.g. after a comma.
Oxford Comma
suggestion

"obstructive casts form in the renal tubules, composed of Bence Jones proteins, immunoglobulins, albumin and Tamm-Horsfall proteins"

Line 83:83 · Use the Oxford comma in 'immunoglobulins, albumin and Tamm'.
Parentheses
suggestion

"Multiple myeloma remains incurable with an estimated median survival of 5.5 years (range 10 years) 14, varying significantly with treatment era and patient fitness. With modern treatment regimens, it exceeds 7-10 years in some cohorts. Management with agents such as thalidomide, lenalidomide, bortezomib (proteasome inhibitor), and daratumumab (CD38 monoclonal antibody) has provided significant survival gains 6. Also, newer agents, including second-generation proteasome inhibitors, additional monoclonal antibodies, and immunotherapies (CAR-T, bispecifics), are increasingly used. These are typically used in combination with older agents such as cyclophosphamide, melphalan, or dexamethasone 6."

Line 191:86 · Use parentheses judiciously. There are at least 3 sets in this paragraph.
Commas
suggestion

"Multiple myeloma remains incurable with an estimated median survival of 5.5 years (range 10 years) 14, varying significantly with treatment era and patient fitness. With modern treatment regimens, it exceeds 7-10 years in some cohorts. Management with agents such as thalidomide, lenalidomide, bortezomib (proteasome inhibitor), and daratumumab (CD38 monoclonal antibody) has provided significant survival gains 6. Also, newer agents, including second-generation proteasome inhibitors, additional monoclonal antibodies, and immunotherapies (CAR-T, bispecifics), are increasingly used. These are typically used in combination with older agents such as cyclophosphamide, melphalan, or dexamethasone 6."

Line 191:470 · More than 5 commas in a single sentence might make it more difficult to read.